GlycoT Therapeutics aims to apply its innovative and proprietary chemoenzymatic glycosylation technology for glycoengineering of therapeutic proteins such as monoclonal antibodies to improve their therapeutic efficacy.
In addition, the company also applies its technology for producing enzymes, oligosaccharides, glycopeptides, and other glycoprotein products as valuable research tools for disease diagnosis and glycobiology research field.
GlycoT was awarded a Phase I SBIR titled "Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation" (1/R43GM146537) with total funding support of $321,239.
GlycoT and Genovis enter into cross-licensing agreements on novel antibody conjugation technology. Under the agreement, Gneovis ( a Sweden publicly traded company) will use the GlycoT's transglycosylation technology to develop research and diagnostic products.
GlycoT Therapeutics has signed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo, a global pharmaceutical company and the second-largest pharmaceutical company in Japan.